Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1704 vs HGP1810 PK and Safety in Healthy Adults
NCT04081857Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Vildagliptin at 24 hours, Area Under the Curve to the Last Measurable Concentration (AUClast) of Vildagliptin at 24 hours and 2 more. Started Jun 2019; status: completed.
02
Drugs
vildagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04081857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081857.